Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Mozambique is seeing a gradual increase in demand due to various factors.
Customer preferences: As the population of Mozambique is increasing, so is the number of cancer patients. The majority of the population prefers to receive treatments from public hospitals due to the high cost of private healthcare. However, public hospitals suffer from a lack of resources, which can lead to treatment delays and inadequate care. Patients are also increasingly interested in alternative treatments, such as herbal remedies, which may be more affordable.
Trends in the market: The Oncology Drugs market in Mozambique is seeing a gradual increase in demand due to various factors. The government has increased its spending on healthcare, which has led to the expansion of the healthcare sector. The demand for cancer treatments has increased due to the rising cancer incidence rates in the country. There has also been an increase in the number of private healthcare facilities, which has led to greater access to cancer treatments. However, the market is still in its early stages of development, and there is a lack of awareness among the general population about the importance of cancer screenings and early detection.
Local special circumstances: Mozambique is one of the poorest countries in the world, and the healthcare system is still in its early stages of development. The country has a shortage of healthcare professionals and a lack of resources, which makes it difficult to provide adequate care to cancer patients. The majority of the population lives in rural areas, which can make it difficult to access healthcare facilities. Additionally, there is a lack of awareness among the general population about the importance of cancer screenings and early detection.
Underlying macroeconomic factors: The Mozambique economy has been growing in recent years, but it is still heavily reliant on agriculture and natural resources. The country has a high poverty rate, and the healthcare system is still in its early stages of development. The government has increased its spending on healthcare, but there is still a long way to go to improve the quality of care. The country has also been affected by political instability and natural disasters, which have hindered economic growth and development.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
